Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering
Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.
How this was made
The 30-second read
Why it matters
Gross proceeds of about $300M are earmarked for R&D, manufacturing capacity expansion, product offerings, working capital, and general corporate purposes. The primary tradable implication is dilution and near-term balance-sheet sentiment.
Market read
A priced, upsized equity offering with defined size and proceeds is a concrete catalyst that can drive short-term repricing and trading volume.
What to watch
The article does not state investor demand, lock-up terms, or whether the offering price reflects a discount to market, all of which can materially change the immediate tape reaction.
Background
Twist Bioscience announced and priced an underwritten public offering, including an option for underwriters to buy additional shares.
Ticker impact
Twist Bioscience priced an upsized underwritten public offering of 3.12M shares at $96, raising about $300M gross proceeds.
Near-term downside bias on dilution risk, with potential stabilization if investors view proceeds as extending runway and de-risking capacity plans.
The article discloses the offering size, price, and use of proceeds, which directly affects capital structure and dilution expectations. No offsetting guidance or demand/underwriting details are provided.
Market effects
Biotech equity issuance can signal ongoing funding needs, potentially affecting sentiment toward cash-burn growth names.
Limited direct regional impact; primarily US-listed biotech sentiment.
Low global relevance beyond biotech financing conditions.
Counterpoint
If the market interprets the offering as well-timed funding for manufacturing scale-up, the stock could rebound after initial dilution selling.
Key entities
- issuerTwist Bioscience Corporation
Priced an upsized underwritten public offering of common stock at $96 per share, with expected close on Aug 6, 2026.
- deal_partiesJoint book-running managers
Goldman Sachs, William Blair, Leerink Partners, and Guggenheim Securities acted as joint book-running managers.
